000056747 001__ 56747
000056747 005__ 20200221144219.0
000056747 0247_ $$2doi$$a10.3390/molecules21070843
000056747 0248_ $$2sideral$$a96124
000056747 037__ $$aART-2016-96124
000056747 041__ $$aeng
000056747 100__ $$aStojkovic, S.
000056747 245__ $$aResistance to DNA Damaging agents produced invasive phenotype of rat glioma cells-characterization of a new in vivo model
000056747 260__ $$c2016
000056747 5060_ $$aAccess copy available to the general public$$fUnrestricted
000056747 5203_ $$aChemoresistance and invasion properties are severe limitations to efficient glioma therapy. Therefore, development of glioma in vivo models that more accurately resemble the situation observed in patients emerges. Previously, we established RC6 rat glioma cell line resistant to DNA damaging agents including antiglioma approved therapies such as 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TMZ). Herein, we evaluated the invasiveness of RC6 cells in vitro and in a new orthotopic animal model. For comparison, we used C6 cells from which RC6 cells originated. Differences in cell growth properties were assessed by real-time cell analyzer. Cells’ invasive potential in vitro was studied in fluorescently labeled gelatin and by formation of multicellular spheroids in hydrogel. For animal studies, fluorescently labeled cells were inoculated into adult male Wistar rat brains. Consecutive coronal and sagittal brain sections were analyzed 10 and 25 days post-inoculation, while rats’ behavior was recorded during three days in the open field test starting from 25th day post-inoculation. We demonstrated that development of chemoresistance induced invasive phenotype of RC6 cells with significant behavioral impediments implying usefulness of orthotopic RC6 glioma allograft in preclinical studies for the examination of new approaches to counteract both chemoresistance and invasion of glioma cells.
000056747 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/DPI2015-65401-C3-1-R$$9info:eu-repo/grantAgreement/ES/MINECO/MTM2015-71200-R
000056747 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000056747 590__ $$a2.861$$b2016
000056747 591__ $$aCHEMISTRY, ORGANIC$$b17 / 59 = 0.288$$c2016$$dQ2$$eT1
000056747 592__ $$a0.824$$b2016
000056747 593__ $$aAnalytical Chemistry$$c2016$$dQ1
000056747 593__ $$aPharmaceutical Science$$c2016$$dQ1
000056747 593__ $$aChemistry (miscellaneous)$$c2016$$dQ1
000056747 593__ $$aOrganic Chemistry$$c2016$$dQ2
000056747 593__ $$aPhysical and Theoretical Chemistry$$c2016$$dQ2
000056747 593__ $$aDrug Discovery$$c2016$$dQ2
000056747 593__ $$aMedicine (miscellaneous)$$c2016$$dQ2
000056747 593__ $$aMolecular Medicine$$c2016$$dQ3
000056747 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000056747 700__ $$aPodolski-Renic, A.
000056747 700__ $$aDinic, J.
000056747 700__ $$aPavkovic, Ž.
000056747 700__ $$0(orcid)0000-0002-9414-1845$$aAyuso, J.M.$$uUniversidad de Zaragoza
000056747 700__ $$aFernández, L.J.
000056747 700__ $$0(orcid)0000-0003-2410-5678$$aOchoa, I.$$uUniversidad de Zaragoza
000056747 700__ $$aPérez-García, V.M.
000056747 700__ $$aPešic, V.
000056747 700__ $$aPešic, M.
000056747 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000056747 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000056747 773__ $$g21, 7 (2016), 21070843[16 p.]$$pMolecules$$tMolecules$$x1420-3049
000056747 8564_ $$s8889233$$uhttps://zaguan.unizar.es/record/56747/files/texto_completo.pdf$$yVersión publicada
000056747 8564_ $$s105336$$uhttps://zaguan.unizar.es/record/56747/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000056747 909CO $$ooai:zaguan.unizar.es:56747$$particulos$$pdriver
000056747 951__ $$a2020-02-21-13:13:46
000056747 980__ $$aARTICLE